IMMUNEONCO-B: INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDERTHE LICENSE AND COLLABORATION AGREEMENT WITHSYNBIOTX FOR IMM2510 AND IMM27M
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS
IMMUNEONCO-B: Next Day Disclosure Return
IMMUNEONCO-B: INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024
IMMUNEONCO-B: INSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE
IMMUNEONCO-B: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPFRONT PAYMENT RECEIVED UNDER THE LICENSE ANDCOLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510AND IMM27M
IMMUNEONCO-B: DATE OF BOARD MEETING
IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024
IMMUNEONCO-B: INSIDE INFORMATION - LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M
IMMUNEONCO-B: (1) RESIGNATION OF SUPERVISOR; AND (2) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OFIMM2510 IN COMBINATION WITH IMM27M
IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH TISLELIZUMAB
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-002
IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML
No Data
No Data